Research Topics
| V D SteenSummaryAffiliation: Georgetown University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pregnancy in women with systemic sclerosisV D Steen
Department of Medicine, Georgetown University, Washington, DC, USA
Obstet Gynecol 94:15-20. 1999..To determine pregnancy outcomes in women with systemic sclerosis...- Long-term outcomes of scleroderma renal crisisV D Steen
Georgetown University, 3800 Reservoir Road NW, LL Gorman, Washington, DC 20007, USA
Ann Intern Med 133:600-3. 2000..Although scleroderma renal crisis, a complication of systemic sclerosis, can be treated with angiotensin-converting enzyme (ACE) inhibitors, its long-term outcomes are not known... - Improvement in skin thickening in systemic sclerosis associated with improved survivalV D Steen
Georgetown University Medical Center, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Washington, DC 20007, USA
Arthritis Rheum 44:2828-35. 2001..The purpose of the present study was to determine whether improvement in skin thickening over time was associated with improved survival... - Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvementVirginia Steen
Georgetown University Medical Center, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Gorman LL Building, 3800 Reservoir NW, Washington, DC 20007, USA
Arthritis Rheum 48:516-22. 2003.... - Treatment of systemic sclerosisV D Steen
Department of Medicine, Georgetown University, Washington, DC, USA
Am J Clin Dermatol 2:315-25. 2001..Although an overall remittive therapy has not yet been determined, new, potentially useful agents are being investigated... - Assessment of kidney involvementV D Steen
Georgetown University School of Medicine, Division of Rheumatology, Allergy and Clinical Immunology, 3800 Reservoir Road, LL Gorman, Washington, DC 20007, USA
Clin Exp Rheumatol 21:S29-31. 2003..In clinical investigations SSc patients developing arterial hypertension after the disease onset (new onset hypertension) without SRC should also be reported... - Development of a provisional core set of response measures for clinical trials of systemic sclerosisD Khanna
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
Ann Rheum Dis 67:703-9. 2008..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)... - Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine studyD Khanna
Division of Immunology, Department of Medicine, University of Cincinnati, ML 0563, Cincinnati, OH 45267 0563, USA
Ann Rheum Dis 65:1325-9. 2006..To estimate minimally important differences (MIDs) in scores for the modified Rodnan Skin Score (mRSS) and Health Assessment Questionnaire-Disability Index (HAQ-DI) in a clinical trial on diffuse systemic sclerosis (SSc)... - The heart in systemic sclerosisVirginia Steen
Georgetown University, 3800 Reservoir Road, LL Gorman, Washington, DC 20007, USA
Curr Rheumatol Rep 6:137-40. 2004..More extensive evaluation of the conduction and the arrhythmia ablative therapy has helped manage these life-threatening complications... - Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosisPhilip J Clements
Divisions of Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Ann Rheum Dis 66:1641-7. 2007..This report examines the differences at baseline and over 12 months between patients with limited versus diffuse cutaneous SSc who participated in the Scleroderma Lung Study... - Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosisVirginia Steen
Georgetown University School of Medicine, Georgetown University, Department of Medicine, LL Gorman, Washington, DC 20007, USA
Chest 134:146-51. 2008..This study looks at the use of an exercise echocardiogram in identifying patients who may have PAH and may be candidates for early therapeutic intervention... - Scleroderma renal crisisVirginia Steen
Indian J Med Sci 61:71-2. 2007 - Cyclophosphamide versus placebo in scleroderma lung diseaseDonald P Tashkin
University of California at Los Angeles, Los Angeles, USA
N Engl J Med 354:2655-66. 2006.... - Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysisOliver Distler
University Hospital Zurich, Zurich, Switzerland
Arthritis Rheum 59:867-75. 2008..The aim of the present study was to establish an expert consensus regarding which outcome measures are most appropriate for clinical trials in PAH-SSc... - Targeted therapy for systemic sclerosisVirginia Steen
Medstar Georgetown University, Division of Rheumatology, Immunology, and Allergy, 3800 Reservoir Road NW, LL Gorman, Washington, DC 20007, USA
Autoimmun Rev 5:122-4. 2006..All of these factors are influenced by unknown inciting agents and the permissive genetic background... - Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelinesMichael McGoon
Mayo Clinic, Rochester, USA
Chest 126:14S-34S. 2004..This article reviews evidence for screening in susceptible patient groups and the approach to diagnosing PAH when it is suspected, and provides specific recommendations for applying this evidence to clinical practice... - Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseDonald P Tashkin
Department of Medicine, David Geffen School of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1690, USA
Am J Respir Crit Care Med 176:1026-34. 2007..Although treatment-related benefits in pulmonary function, skin scores, and patient-centered outcomes were demonstrated after 1 year of therapy, the duration of benefit beyond 1 year was unclear... - A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase diArnold E Postlethwaite
University of Tennessee, Memphis, and VAMC, Memphis
Arthritis Rheum 58:1810-22. 2008..To investigate the safety and efficacy of oral bovine type I collagen (CI) treatment in patients who have had diffuse cutaneous systemic sclerosis (dcSSc; scleroderma) for <or=10 years... - Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trialPaul J DeMarco
Marshfield Clinic, Wausau, Wisconsin, USA
Arthritis Rheum 46:2983-9. 2002..Although ACE inhibitors and dialysis are now readily available, SRC continues to be associated with poor survival (in this study, 50% of patients with SRC died)... - Systemic sclerosis - continuing progress in developing clinical measures of responseDaniel Furst
University of California at Los Angeles, Los Angeles, California 90025, USA
J Rheumatol 34:1194-200. 2007..Another Delphi exercise is designed to develop consensus regarding a combined SSc response index to be validated in future RCT... - Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung studyDinesh Khanna
University of Cincinnati, Cincinnati, Ohio 45267 0563, USA
Arthritis Rheum 56:1676-84. 2007..To assess the impact of cyclophosphamide (CYC) on the health-related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment... - High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learnedPhilip J Clements
Division of Rheumatology, UCLA School of Medicine, Los Angeles, CA 90095 1670, USA
Semin Arthritis Rheum 33:249-63. 2004..To review important findings, or lessons, that were learned about measures of response, design, conduct, and analysis of a randomized, controlled trial (RCT), even though the trial failed to demonstrate efficacy of d-penicillamine... - Advancements in diagnosis of pulmonary arterial hypertension in sclerodermaVirginia Steen
Arthritis Rheum 52:3698-700. 2005 - High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung diseaseJonathan G Goldin
David Geffen School of Medicine at UCLA, Department of Radiology, Los Angeles, CA 90095 1721, USA
Chest 134:358-67. 2008..The frequency, nature, and progression of interstitial lung disease seen on high-resolution CT (HRCT) scans in patients with diffuse SSc (dcSSc) compared with those with limited SSc (lcSSc) has not been well characterized...